血管质量倡议-医保索赔关联数据库中2型内漏发生率高但相关不良事件低
该回顾性研究利用血管质量倡议-医保索赔关联数据,纳入2015至2017年首次接受EVAR的5534例患者,评估2型内漏(T2EL)的预后及预防性分支血管栓塞(PBE)的作用。结果显示T2EL发生率为24.7%,3年死亡率、再干预率无差异,自发消退率73.7%,PBE后无T2EL者瘤囊回缩最明显。
要点
- T2EL发生率高(24.7%),但3年死亡率、影像检查及再干预率与无T2EL者无差异
- T2EL自发消退率73.7%,多供血血管者自发消退率最低(54.9%)
- 预防性分支血管栓塞(PBE)联合EVAR在部分情况下可能适用
核心结论
- EVAR术后T2EL与高自发消退率、低瘤囊增长率和早期死亡率或再干预率不增加相关。
- 预防性分支血管栓塞联合EVAR在部分情况下可能适用。
研究设计与样本
- 回顾性研究,使用血管质量倡议-医保索赔关联数据库,纳入2015至2017年首次接受EVAR的患者,最终队列5534例。
- 排除完成血管造影存在非T2EL内漏者、无血管质量倡议影像随访者、无医保A或B部分参保者及无1年完整医保随访数据者。
- 暴露变量为T2EL,定义为术后第一年内检测到任何分支血管血流。
主要发现
- 最终队列5534例中,1372例(24.7%)存在T2EL,4162例(75.2%)无T2EL;有和无T2EL患者的中位年龄分别为77岁和75岁。
- T2EL患者术后3年死亡率、影像检查、再干预或T2EL相关再干预均无差异。
- 总队列瘤囊直径中位缩小4 mm(范围:缩小9-0 mm);肠系膜下动脉源性T2EL瘤囊缩小幅度最小(中位缩小1 mm,对比副肾动脉源性1.5 mm、多供血血管源性2 mm、腰动脉源性4 mm;P < .001)。
- 自发消退发生于73.7%的患者(n = 809);多供血血管T2EL自发消退率最低(n = 51,54.9%),对比单供血血管肠系膜下动脉(n = 99,60.0%)、腰动脉(n = 655,77.7%)或副肾动脉(n = 31,79.5%)(P < .001)。
- 84例患者接受预防性分支血管栓塞;接受PBE且EVAR后未检测到T2EL者随访时瘤囊回缩幅度最大(较基线缩小7 mm)。
临床怎么用
- 作者认为,预防性分支血管栓塞联合EVAR在部分情况下可能适用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Type 2 endoleak (T2EL) is the most common adverse finding on postoperative surveillance after endovascular aortic aneurysm repair (EVAR). A low rate of aneurysm-related mortality with T2EL has been established. However, the optimal management strategy and the efficacy of reintervention remain controversial. This study used data from the Vascular Quality Initiative linked to Medicare claims (VQI-Medicare) to evaluate T2LE in a real-world cohort. METHODS: This retrospective review of EVAR procedures in VQI-Medicare included patients undergoing their first EVAR procedure between 2015 and 2017. Patients with an endoleak other than T2EL on completion angiogram and those without VQI imaging follow-up were excluded. Patients without Medicare part A or part B enrollment at the time of the procedure or without 1-year complete Medicare follow-up data were also excluded. The exposure variable was T2EL, defined as any branch vessel flow detected within the first postoperative year. Outcomes of interest were mortality, reintervention, T2EL-related reintervention, post-EVAR imaging, and T2EL behavior including spontaneous resolution, aneurysm sac regression, and resolution after reintervention. The association of prophylactic branch vessel embolization (PBE) with T2EL resolution and aneurysm sac regression was also evaluated. RESULTS: In a final cohort of 5534 patients, 1372 (24.7%) had an identified T2EL and 4162 (75.2%) did not. The median age of patients with and without T2EL was 77 and 75 years, respectively. There were no differences in mortality, imaging, reintervention, or T2EL-related reintervention at 3 years after the procedure for patients with T2EL. The aneurysm sac diameter decreased by 4 mm (range: 9-0 mm decrease) in the total cohort. Patients with inferior mesenteric artery-based T2EL had the smallest decrease in aneurysm diameter (median 1 mm decrease compared with 1.5 mm for accessory renal artery-based T2EL, 2 mm for multiple feeding vessel-based T2EL, and 4 mm for lumbar artery-based T2EL; P < .001). Spontaneous resolution occurred in 73.7% of patients (n = 809). T2ELs with evidence of multiple feeding vessels were associated with the lowest rate of spontaneous resolution (n = 51, 54.9%), compared with those with a single identified feeding vessel of inferior mesenteric artery (n = 99, 60.0%), lumbar artery (n = 655, 77.7%), or accessory renal artery (n = 31, 79.5%) (P < .001). PBE was performed in 84 patients. Patients who underwent PBE and were without detectable T2EL after EVAR had the greatest rate of sac regression at follow-up (7 mm decrease) compared with baseline. CONCLUSIONS: T2EL after EVAR is associated with high rates of spontaneous resolution, low rates of aneurysm sac growth, and no evidence of increased early mortality or reintervention. PBE in conjunction with EVAR may be indicated in some circumstances.
引用
- Mansukhani NA, Brown KR, Zheng X, et al. High incidence of type 2 endoleak and low associated adverse events in the Vascular Quality Initiative linked to Medicare claims. J Vasc Surg. 2023. PMID: 37086823. doi:10.1016/j.jvs.2023.04.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。